Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil for Fontan Associated Liver Disease
NCT03154476Phase 3Completed
- Sponsor
- Mayo Clinic
- Start
- Jul 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sildenafil in Fontan-associated liver disease (FALD), sponsored by Mayo Clinic. Started Jul 2017; status: completed.
02
Drugs
sildenafil
03
Conditions
Fontan-associated liver disease (FALD)
Beyond the preview
Go deeper on NCT03154476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03154476.